Search results for "biosimilar"
Article
3rd BioProcessing Asia Preview: Q&A with John Curling
The program always covers the entire biopharmaceutical spectrum from antibodies and blood plasma products to vaccines as well as biosimilars development. BioProcessing Asia also differentiates itself …
Article
Process Development: What May Lie Ahead in 2018?
Such next-gen antibodies include antibody drug conjugates, engineered antibodies, bispecific antibodies, antibody fragments, antibody-like proteins and biosimilar antibody therapies.
The productio…
Article
From Darwin to Recombinant Fc Multimers
no biosimilars
• Continued innovation, investment and progress
To ensure future vitality of the industry, Perkins talked about the importance of securing plasma supply, donor and patient safet…
Article
Witnessing Major Growth in Next-Generation Antibodies
The global market for next-generation antibodies, including antibody drug conjugates (ADCs), engineered antibodies, bispecific antibodies, antibody fragments, antibody-like proteins and biosimilar ant…
Article
Speed and Flexibility Are Dual Goals for Biopharma Operations
…acilities and production lines to accommodate clinical trial and commercial needs for innovator and biosimilar drugs. With speed to market a prime objective, prefabricated and modular production faci…
Article
Single-use Bioreactors Have Reached the Big Time
…ocesses, the growth of biologics targeting smaller patient populations and the expanding demand for biosimilars in emerging markets has meant that total output needs now fit within the capable produc…
Article
Make buffer preparation more time and cost efficient with inline conditioning
Simplify Buffer Preparation
The volume and number of buffers for a typical downstream process can be considerable.
Preparation of these buffers is a challenge that in-line conditioning can o…
Article
A Q&A on Bioprocessing Trends and Technologies at INTERPHEX 2016
One sign of progress was the opening of a JHL Biotech flexible manufacturing facility in Wuhan, China on May 10, 2016, for the manufacture of biosimilars and monoclonal antibodies (mAbs). The facility…
Article
Continuous Processing for the Production of Biopharmaceuticals
With the growing demand for biosimilars and an ever-increasing pressure for reduction in manufacturing costs, the biotech industry seems to exhibit a flourishing interest in the development of continu…
Poster
Modes of controlling charge variant distribution in Mab production
The characteristics of a biological drug, for example, charge variant profile, are determined to a large extent by the upstream expression system and conditions, but can also be influenced by the pu…